In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Abeona Therapeutics (ABEO), with a price target of $8.00. The company’s shares closed last Friday at $1.91.
According to TipRanks.com, Selvaraju is a top 100 analyst with an average return of 33.2% and a 70.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Protalix Biotherapeutics, NeuroBo Pharmaceuticals, and Inovio Pharmaceuticals.
Currently, the analyst consensus on Abeona Therapeutics is a Moderate Buy with an average price target of $5.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.34 and a one-year low of $0.99. Currently, Abeona Therapeutics has an average volume of 2.45M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
